Table 2.
Adjusted Cox hazards regression models for specific opportunistic illnesses for patients who did not use combination antiretroviral therapy (n = 2750 individuals)
| Tuberculosis | Esophageal candidiasis | Cerebral Toxoplamosis | PCP | |
|---|---|---|---|---|
| (N = 147) | (N = 90) | (N = 58) | (N = 47) | |
| HR (CI) | HR (CI) | HR (CI) | HR (CI) | |
| Gender-Risk | ||||
| Women | Ref. | Ref. | Ref. | Ref. |
| Heterosexual men | 1.29 (0.85–1.95) | 0.71 (0.43–1.19) | 0.67 (0.35–1.26) | 2.10 (0.91–4.84) |
| MSM | 1.45 (0.95–2.20) | 1.02 (0.61–1.71) | 0.89 (0.46–1.71) | 1.97 (0.84–4.64) |
| Age (per year) | 0.98 (0.96–1.00) | 1.03 (1.00–1.04) | 1.00 (0.97–1.03) | 1.01 (0.98–1.04) |
| Race/ethnicity | ||||
| White | Ref. | Ref. | Ref. | Ref. |
| Non-white | 1.47 (1.04–2.06) | 1.29 (0.83–2.00) | 1.40 (0.80–2.45) | 0.71 (0.39–1.31) |
| Educational level | ||||
| 0–8 years | 1.64 (1.14–2.35) | 1.41 (0.88–2.26) | 1.39 (0.77–2.53) | 0.71 (0.38–1.33) |
| 9+ years | Ref. | Ref. | Ref. | Ref. |
| Nadir CD4+ T lymphocyte (per 100 cells/mm3) | 0.79 (0.70–0.89) | 0.74 (0.62–0.89) | 0.62 (0.48–0.81) | 0.58 (0.43–0.79) |
| Opportunistic illness at enrollment | 1.61 (1.04–2.52) | 6.27 (3.94–9.96) | 5.65 (3.23–9.89) | 4.10 (2.15–7.82) |
PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
Bold font implies statistically significant results assuming a 5 % significance threshold